{
    "root": "2f34fcf2-de23-f65c-e063-6394a90a86e1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "QUETIAPINE FUMARATE",
    "value": "20250228",
    "ingredients": [
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "HYPROMELLOSE 2208 (4000 MPA.S)",
            "code": "39J80LT57T"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "QUETIAPINE FUMARATE",
            "code": "2S3PL1B6UJ"
        }
    ],
    "indications": "quetiapine extended-release tablet atypical antipsychotic indicated treatment : schizophrenia ( 1.1 ) bipolar disorder , manic , mixed episodes ( 1.2 ) bipolar disorder , depressive episodes ( 1.2 ) major depressive disorder , adjunctive therapy antidepressants ( 1.3 )",
    "contraindications": "swallow tablets whole split , chew crush ( 2.1 ) take without food light meal ( approx . 300 calories ) ( 2.1 ) administer daily , preferably evening ( 2.1 ) geriatric : consider lower starting dose ( 50 mg/day ) , slower titration , careful monitoring initial dosing period elderly . ( 2.3 , 8.5 ) hepatic impairment : lower starting dose ( 50 mg/day ) slower titration may needed ( 2.4 , 8.7 , 12.3 ) indication initial dose recommended dose maximum dose schizophrenia- adults ( 2.2 ) 300 mg/day 400 800 mg/day 800 mg/day schizophrenia-adolescents ( 13 17 years ) ( 2.2 ) 50 mg/day 400 800 mg/day 800 mg/day bipolar disorder manic mixed-acute monotherapy adjunct lithium divalproex-adults ( 2.2 ) 300 mg/day 400 800 mg/day 800 mg/day bipolar disorder , manic acute monotherapy -children adolescents ( 10 17 years ) ( 2.2 ) 50 mg/day 400 600 mg/day 600 mg/day bipolar disorder , depressive episodes-adults ( 2.2 ) 50 mg/day 300 mg/day 300 mg/day major depressive disorder , adjunctive therapy antidepressants-adults ( 2.2 ) 50 mg/day 150 300 mg/day 300 mg/day",
    "warningsAndPrecautions": "quetiapine extended-release tablets , usp 400 mg ( ndc 16729-097 ) white colored , round shaped , biconvex , beveled edge , film coated tablets , debossed \u201c i4 \u201d one side plain supplied ndc : 70518-1841-00 ndc : 70518-1841-01 ndc : 70518-1841-02 packaging : 30 1 box packaging : 1 1 pouch packaging : 30 1 blister pack store quetiapine extended-release tablets , usp 20\u00bac 25\u00bac ( 68 \u00baf 77 \u00baf ) . [ usp controlled room temperature ] . repackaged distributed : remedy repack , inc. 625 kolter dr. suite # 4 indiana , pa 1-724-465-8762",
    "adverseReactions": "hypersensitivity quetiapine excipients quetiapine extended-release tablets formulation . anaphylactic reported patients treated quetiapine extended-release tablets .",
    "indications_original": "Quetiapine Extended-release tablet is an atypical antipsychotic indicated for the treatment of: Schizophrenia (1.1) Bipolar I disorder, manic, or mixed episodes (1.2) Bipolar disorder, depressive episodes (1.2) Major depressive disorder, adjunctive therapy with antidepressants (1.3)",
    "contraindications_original": "Swallow tablets whole and do not split, chew or crush (2.1) Take without food or with a light meal (approx. 300 calories) (2.1) Administer once daily, preferably in the evening (2.1) Geriatric Use: Consider a lower starting dose (50 mg/day), slower titration, and careful monitoring during the initial dosing period in the elderly. ( 2.3 , 8.5 ) Hepatic Impairment: Lower starting dose (50 mg/day) and slower titration may be needed ( 2.4 , 8.7 , 12.3 ) Indication Initial Dose Recommended Dose Maximum Dose Schizophrenia- Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Schizophrenia-Adolescents (13 to 17 years )(2.2) 50 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder manic or mixed-Acute monotherapy or adjunct to lithium or divalproex-Adults (2.2) 300 mg/day 400 to 800 mg/day 800 mg/day Bipolar I Disorder, manic Acute monotherapy -Children and Adolescents (10 to 17 years) (2.2) 50 mg/day 400 to 600 mg/day 600 mg/day Bipolar Disorder, Depressive Episodes-Adults (2.2) 50 mg/day 300 mg/day 300 mg/day Major Depressive Disorder, Adjunctive Therapy with Antidepressants-Adults (2.2) 50 mg/day 150 to 300 mg/day 300 mg/day",
    "warningsAndPrecautions_original": "Quetiapine Extended-release tablets, USP 400 mg (NDC 16729-097) white colored, round shaped, biconvex, beveled edge, film coated tablets, debossed with \u201cI4\u201d on one side and plain on the other is supplied in\n                  NDC: 70518-1841-00\n                  NDC: 70518-1841-01\n                  NDC: 70518-1841-02\n                  PACKAGING: 30 in 1 BOX\n                  PACKAGING: 1 in 1 POUCH\n                  PACKAGING: 30 in 1 BLISTER PACK\n                  \n                  Store quetiapine extended-release tablets, USP at 20\u00baC to 25\u00baC (68 \u00baF to 77 \u00baF). [See USP Controlled Room Temperature].\n                  \n                  Repackaged and Distributed By:\n                  Remedy Repack, Inc.\n                  625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762",
    "adverseReactions_original": "Hypersensitivity to quetiapine or to any excipients in the quetiapine extended-release tablets formulation. Anaphylactic reactions have been reported in patients treated with quetiapine extended-release tablets."
}